Many people don’t know they’re eligible. | Moderna has identified a fundamental barrier to vaccination: many people don’t ...

Moderna shares rebound after six days of losses. Analysts mixed on stock with Strong Sell rating but potential for future growth.

Moderna is focusing on respiratory vaccines to sustain revenue streams amid COVID-19 declines. See more on MRNA stock and its ...

A WhatsApp message has earned Moderna a reprimand from the UK's Prescription Medicines Code of Practice Authority (PMCPA), ...

For a drugmaker advancing medicines through clinical trials, time is the enemy: the longer the process takes, the more costs ...

The biotech industry is buzzing with exciting changes, and a lot of it is thanks to one company: Moderna. Known for its COVID ...

We recently looked at Goldman Sachs’ List Of Stocks That Hedge & Mutual Funds Love & Hate: 28 Stocks On The Mutual and Hedge ...

There are currently no licensed vaccines to treat norovirus, a highly contagious virus that causes sickness and diarrhoea.

In recent years, the biotech industry has seen a lot of exciting changes, and much of that is thanks to one company: Moderna.

Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers’ 2024 Top Employers Survey for the tenth consecutive ...

Northwestern filed a lawsuit against Moderna Wednesday alleging the company misused the University’s patented lipid ...

Nineteen companies are receiving $21.4 million total in tax incentive awards to create 1,155 new life sciences jobs in ...